<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ciclesonide versus other inhaled corticosteroids for chronic asthma in children - Kramer, S - 2013 | Cochrane Library</title> <meta content="Ciclesonide versus other inhaled corticosteroids for chronic asthma in children - Kramer, S - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010352/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ciclesonide versus other inhaled corticosteroids for chronic asthma in children - Kramer, S - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010352/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010352" name="dc.identifier" scheme="DOI"/> <meta content="Ciclesonide versus other inhaled corticosteroids for chronic asthma in children" name="citation_title"/> <meta content="Sharon Kramer" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="sharon.kramer@monash.edu" name="citation_author_email"/> <meta content="Bart L Rottier" name="citation_author"/> <meta content="Beatrix Childrens Hospital, University Medical Center Groningen" name="citation_author_institution"/> <meta content="Rob JPM Scholten" name="citation_author"/> <meta content="Academic Medical Center" name="citation_author_institution"/> <meta content="Nicole Boluyt" name="citation_author"/> <meta content="Emma Children's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD010352" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010352/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010352/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010352/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [*administration &amp; dosage, adverse effects]; Androstadienes [administration &amp; dosage, adverse effects]; Anti‐Asthmatic Agents [*administration &amp; dosage, adverse effects]; Asthma [*drug therapy]; Budesonide [administration &amp; dosage, adverse effects]; Fluticasone; Pregnenediones [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010352&amp;doi=10.1002/14651858.CD010352&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010352\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010352\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010352",title:"Ciclesonide versus other inhaled corticosteroids for chronic asthma in children",firstPublishedDate:"Feb 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010352&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010352';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010352/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010352/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010352%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010352/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010352/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010352/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010352/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010352" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010352/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010352" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010352/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010352/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3235 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010352" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010352/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/appendices#CD010352-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/table_n/CD010352StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/table_n/CD010352StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010352/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010352/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010352/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010352/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010352/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ciclesonide versus other inhaled corticosteroids for chronic asthma in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010352/information#CD010352-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sharon Kramer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010352/information#CD010352-cr-0003">Bart L Rottier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010352/information#CD010352-cr-0004">Rob JPM Scholten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010352/information#CD010352-cr-0005">Nicole Boluyt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010352/information/en#CD010352-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010352/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010352">https://doi.org/10.1002/14651858.CD010352</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010352-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010352-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010352-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010352-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010352-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010352-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010352-abs-0001" lang="en"> <section id="CD010352-sec-0001"> <h3 class="title" id="CD010352-sec-0001">Background</h3> <p>Inhaled corticosteroids (ICS) are the cornerstone of asthma maintenance treatment in children. Particularly among parents, there is concern about the safety of ICS as studies in children have shown reduced growth. Small‐particle‐size ICS targeting the smaller airways have improved lung deposition and effective asthma control might be achieved at lower daily doses. </p> <p>Ciclesonide is a relatively new ICS. This small‐particle ICS is a pro‐drug that is converted in the airways to an active metabolite and therefore with potentially less local (throat infection) and systemic (reduced growth) side effects. It can be inhaled once daily, thereby possibly improving adherence. </p> </section> <section id="CD010352-sec-0002"> <h3 class="title" id="CD010352-sec-0002">Objectives</h3> <p>To assess the efficacy and adverse effects of ciclesonide compared to other ICS in the management of chronic asthma in children. </p> </section> <section id="CD010352-sec-0003"> <h3 class="title" id="CD010352-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Register of trials with pre‐defined terms. Additional searches of MEDLINE (via PubMed), EMBASE and Clinicalstudyresults.org were undertaken. Searches are up to date to 7 November 2012. </p> </section> <section id="CD010352-sec-0004"> <h3 class="title" id="CD010352-sec-0004">Selection criteria</h3> <p>Randomised controlled parallel or cross‐over studies were eligible for the review. We included studies comparing ciclesonide with other corticosteroids both at nominally equivalent doses or lower doses of ciclesonide. </p> </section> <section id="CD010352-sec-0005"> <h3 class="title" id="CD010352-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. </p> </section> <section id="CD010352-sec-0006"> <h3 class="title" id="CD010352-sec-0006">Main results</h3> <p>Six studies were included in this review (3256 children, 4 to 17 years of age). Two studies were published as conference abstracts only. Ciclesonide was compared to budesonide and fluticasone. </p> <p>Ciclesonide compared to budesonide (dose ratio 1:2): asthma symptoms and adverse effect were similar in both groups. Pooled results showed no significant difference in children who experience an exacerbation (risk ratio (RR) 2.20, 95% confidence interval (CI) 0.75 to 6.43). Both studies reported that 24‐hour urine cortisol levels showed a statistically significant decrease in the budesonide group compared to the ciclesonide group. </p> <p>Ciclesonide compared to fluticasone (dose ratio 1:1): no significant differences were found for the outcome asthma symptoms. Pooled results showed no significant differences in number of patients with exacerbations (RR 1.37, 95% CI 0.58 to 3.21) and data from a study that could not be pooled in the meta‐analysis reported similar numbers of patients with exacerbations in both groups. None of the studies found a difference in adverse effects. No significant difference was found for 24‐hour urine cortisol levels between the groups (mean difference 0.54 nmol/mmol, 95% CI ‐5.92 to 7.00). </p> <p>Ciclesonide versus fluticasone (dose ratio 1:2) was assessed in one study and showed similar results between the two corticosteroids for asthma symptoms. The number of children with exacerbations was significantly higher in the ciclesonide group (RR 3.57, 95% CI 1.35 to 9.47). No significant differences were found in adverse effects (RR 0.98, 95% CI 0.81 to 1.14) and 24‐hour urine cortisol levels (mean difference 1.15 nmol/mmol, 95% CI 0.07 to 2.23). </p> <p>The quality of evidence was judged 'low' for the outcomes asthma symptoms and adverse events and 'very low' for the outcome exacerbations for ciclesonide versus budesonide (dose ratio 1:1). The quality of evidence was graded 'moderate' for the outcome asthma symptoms, 'very low' for the outcome exacerbations and 'low' for the outcome adverse events for ciclesonide versus fluticasone (dose ratio 1:1). For ciclesonide versus fluticasone (dose ratio 1:2) the quality was rated 'low' for the outcome asthma symptoms and 'very low' for exacerbations and adverse events (dose ratio 1:2). </p> </section> <section id="CD010352-sec-0007"> <h3 class="title" id="CD010352-sec-0007">Authors' conclusions</h3> <p>An improvement in asthma symptoms, exacerbations and side effects of ciclesonide versus budesonide and fluticasone could be neither demonstrated nor refuted and the trade‐off between benefits and harms of using ciclesonide instead of budesonide or fluticasone is unclear. The resource use or costs of different ICS should therefore also be considered in final decision making.   </p> <p>Longer‐term superiority trials are needed to identify the usefulness and safety of ciclesonide compared to other ICS. Additionally these studies should be powered for patient relevant outcomes (exacerbations, asthma symptoms, quality of life and side effects). There is a need for studies comparing ciclesonide once daily with other ICS twice daily to assess the advantages of ciclesonide being a pro‐drug that can be administered once daily with possibly increased adherence leading to increased control of asthma and fewer side effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010352-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010352-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010352-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010352-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010352-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010352-abs-0006">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010352-abs-0005" lang="en"> <h3>Ciclesonide compared to budesonide and fluticasone in the treatment of asthma in children</h3> <p>Asthma is a common disease in childhood. Most children with chronic asthma are treated with inhaled corticosteroids (ICS) to control airway inflammation and reduce asthma symptoms. Although these drugs are considered to be very safe and effective, not all children achieve full asthma control and some parents are concerned about the possibility of reduced growth or local side effects such as hoarseness. The challenge for newer ICS is to achieve improved asthma control with fewer side effects. This could be achieved by small‐particle‐size ICS, leading to better lung deposition as they penetrate deeper into the small airways. Therefore, asthma control could be achieved with lower daily doses and with fewer side effects. In children, particle size of ICS might be even more important because of their smaller airways. </p> <p>Ciclesonide is a new small‐particle‐size ICS. The smaller particle size may make the corticosteroid go deeper into the lungs. Potential advantages are a lower required dose to achieve asthma control, once daily instead of twice daily dosing, and reduced local (oral thrush) and systemic (growth suppression) side effects. </p> <p>We found six studies comparing ciclesonide with either budesonide or fluticasone in 3256 children (aged four to 17 years) with chronic asthma. After three months of treatment with ciclesonide compared to budesonide or fluticasone, no relevant differences could be found on asthma symptoms, exacerbations or side effects. Ciclesonide compared to a double dose of fluticasone was assessed in one study and no differences were found in asthma symptoms, use of rescue medication and adverse effects. However, children receiving ciclesonide experienced more asthma exacerbations than children in the fluticasone group. </p> <p>The results of this review regarding the efficacy and safety of ciclesonide compared to other ICS are not conclusive. Relatively few studies were found, different inhalers were compared and treatment and follow‐up time (12 weeks) was too short for the assessment of relevant outcomes such as exacerbations and growth retardation. Future studies should pay attention to those aspects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010352-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010352-sec-0088"></div> <h3 class="title" id="CD010352-sec-0089">Implications for practice</h3> <section id="CD010352-sec-0089"> <p>A beneficial effect on asthma symptoms, exacerbations and side effects of ciclesonide versus budesonide or fluticasone could be neither demonstrated nor refuted. Ciclesonide was non‐inferior compared to budesonide or fluticasone in terms of lung function end points and in some studies less suppression on cortisol outcomes was demonstrated. </p> <p>New medications should either be more effective, safer or cheaper before they can be recommended for clinical practice. Because older medications have been used for longer periods of time, more knowledge is available on their long‐term safety and they are usually cheaper than new drugs (resource use). As far as we are aware there were few data available for the cost‐effectiveness of ciclesonide compared to other ICS. </p> <p>Several other considerations must be taken into account before making clinical decisions, such as the trade‐off between benefits and harms, patient preferences and values, and resource use. The importance of these considerations can differ among different countries and cultures, leading to different recommendations for practice. For patient and parents, long‐term safety of ICS is an important issue. Well‐designed long‐term safety studies for ciclesonide are lacking. We cannot exclude that children receiving ciclesonide experience more exacerbations, as the CIs included potential harm as well as benefit. Therefore, the trade‐off between benefits and harms of using ciclesonide instead of budesonide or fluticasone is unclear. </p> <p>An advantage of ciclesonide over other ICS is that it is licensed for once‐daily use, which could enhance compliance (<a href="./references#CD010352-bbs2-0054" title="OsterbergL , BlaschkeT . Adherence to medication. New England Journal of Medicine2005;353(5):487‐97. ">Osterberg 2005</a>), particularly in patients where compliance is a problem. Although ciclesonide is not registered for use with an AeroChamber® in paediatric practice, it is common to use a spacer device and AeroChamber Plus® is an adequate choice based on the low plume velocity of the ciclesonide‐pMDI. In addition, several studies have also used an AeroChamber® to deliver ciclesonide (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0025" title="PedersenS , PotterP , DachevS , BoshevaM , KaczmarekJ , SpringerE , et al. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the Rainbow study. Respiratory Medicine2010;104(11):1618‐28. ">Pedersen 2010</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). In the end, resource use or costs of different ICS should be considered in final decision making. </p> </section> <h3 class="title" id="CD010352-sec-0090">Implications for research</h3> <section id="CD010352-sec-0090"> <p>Based on this review a number of recommendations can be made for future trials. First, instead of non‐inferiority studies, superiority trials are needed to identify the efficacy and safety of ciclesonide compared to other ICS. In addition, these studies should be powered for patient‐relevant outcomes (exacerbations, asthma symptoms, quality of life and side effects) and not only on surrogate endpoints such as lung function and cortisol. </p> <p>Studies comparing ciclesonide once daily with other ICS twice daily should be conducted, to test the advantages of ciclesonide being a pro‐drug that can be administered once daily. Once daily administration versus twice daily may result in increased adherence and to increased control of asthma and fewer side effects. In general, studies of at least six to 12 months' duration are needed to compare the relative benefits and side effects of the various ICS and their ways of administration on the longer term. Finally, inhaler devices and inhaler techniques needs to be taken into consideration in designing future trials and ideally, two doses of each drug‐device combination should be compared to two doses of the comparator drug‐device combination. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010352-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010352-sec-0029"></div> <div class="table" id="CD010352-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> budesonide (dose ratio 1:2) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide (dose ratio 1:2)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies used a 5‐point scale, but insufficient data were reported to allow meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (9 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.2</b> <br/> (0.75 to 6.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data could not be meta‐analysed because the definitions of adverse events were too diverse </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> In one study the dose of budesonide was much higher than what is commonly prescribed in clinical practice. <br/> <sup>2</sup> Both studies were sponsored by the manufacturer and at least one of the authors of each study was an employee of the manufacturer that sponsored the study. <br/> <sup>3</sup> The intervention period of 12 weeks was too short to expect any major changes in this outcome. <br/> <sup>4</sup> Confidence intervals of estimated effect include no effect and exceed a relative reduction or increase risk of 25%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010352-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> fluticasone (dose ratio 1:1) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone (dose ratio 1:1)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies used a 5‐point scale and 1 study did not provide details how asthma symptoms were measured. Data could not be pooled due to diversity in scales </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (10 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.37</b> <br/> (0.58 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1003 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1560 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were defined differently across studies therefore results could not be pooled </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Two fully published studies were sponsored by the manufacturer and at least one of the authors of each study was an employee of the manufacturer that sponsored the study. <br/> <sup>2</sup> The intervention period of 12 weeks is too short to expect any major changes in this outcome. <br/> <sup>3</sup> Confidence intervals of estimated effect include no effect and exceed a relative reduction or increase risk of 25%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010352-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> fluticasone (dose ratio 1:2) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone (dose ratio 1:2)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptom</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean asthma symptom in the control groups was <br/> <b>1.33</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean asthma symptom in the intervention groups was <br/> <b>0.07 higher</b> <br/> (0.14 to 0.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estimates are medians indicating data was skewed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (27 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.48</b> <br/> (1.35 to 8.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>476 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> <br/> (424 to 514) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.89 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Based on one study that was underpowered for a non‐inferiority trial. <br/> <sup>2</sup> The study was sponsored by the manufacturer and at least one author was an employee of the manufacturer that sponsored the study. <br/> <sup>3</sup> The intervention period of 12 weeks is too short to expect any major changes in this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010352-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010352-sec-0030"></div> <section id="CD010352-sec-0031"> <h3 class="title" id="CD010352-sec-0031">Description of the condition</h3> <p>Asthma is the most common chronic disease of childhood with a prevalence of 8% to 15% (<a href="./references#CD010352-bbs2-0053" title="MasoliM , FabianD , HoltS , BeasleyR . Developed for Global Initiative for Asthma (GINA). Allergy2004;59:469‐78. [Full report available on www.ginasthma.com] ">Masoli 2004</a>). It is a chronic inflammatory disease affecting the whole airway system, including the small airways (<a href="./references#CD010352-bbs2-0044" title="HamidQ , SongY , KotsimbosTC , MinshallE , BaiTR , HegeleRG , et al. Inflammation of small airways in asthma. Journal of Allergy and Clinical Immunology1997;100(1):44‐51. ">Hamid 1997</a>). Daily inhaled corticosteroids (ICS) are the cornerstone of treatment of chronic asthma and in recent guidelines ICS are recommended for all patients except those with mild, intermittent symptoms (<a href="./references#CD010352-bbs2-0034" title="British Thoracic Society. British Guideline on the Management of Asthma: A National Clinical Guideline, 2011. www.sign.ac.uk/guidelines/fulltext/101/index.html. (accessed 14 December 2012). ">British Thoracic Society 2011</a>; <a href="./references#CD010352-bbs2-0042" title="Global Initiative for Asthma(GINA) . Global Strategy for Asthma Management and Prevention, 2011. www.ginasthma.com. (accessed 14 December 2012). ">GINA 2011</a>). </p> </section> <section id="CD010352-sec-0032"> <h3 class="title" id="CD010352-sec-0032">Description of the intervention</h3> <p>ICS reduce inflammation in the lungs by modulating the inflammatory response of the lung by binding to the glucocorticoid receptor and suppressing the expression of pro‐inflammatory genes. With asthmatic inflammation occurring in all airways including the small airways, the challenge of ICS treatment has now focused mainly on targeting the small airways (<a href="./references#CD010352-bbs2-0040" title="GelflandEW , KraftM . The importance of features of the distal airways in children and adults. Journal of Allergy and Clinical Immunology2009;124(6 suppl):S84‐7. ">Gelfand 2009</a>; <a href="./references#CD010352-bbs2-0048" title="LahzamiS , KingGG . Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment. European Respiratory Journal2008;31(6):1145‐7. ">Lahzami 2008</a>). Small‐particle drugs (median diameter 1.5 µm) penetrate better in the small airways and improve total lung deposition in adults, more so when inhaled with slower inspiratory flows (<a href="./references#CD010352-bbs2-0062" title="UsmaniOS , BiddiscombeMF , BarnesPJ . Regional lung deposition and bronchodilator response as a function of beta2‐agonist particle size. American Journal of Respiratory Critical Care Medicine2005;172(12):1497‐504. ">Usmani 2005</a>). </p> <p>Potential adverse drug effects of ICS can be divided into local (such as oral candidiasis and hoarseness) and systemic (adrenal and growth suppression) effects. Particularly in children growth is still a major concern for parents and clinicians. Several longitudinal studies evaluating the effect of ICS on growth have shown a small decrease in growth velocity (approximately 1 to 2 cm) during the first year of treatment (<a href="./references#CD010352-bbs2-0055" title="PetersSP . Safety of inhaled corticosteroids in the treatment of persistent asthma. Journal of the National Medical Association2006;98(6):851‐61. ">Peters 2006</a>). However, long‐term follow‐up studies show no change in final adult height (<a href="./references#CD010352-bbs2-0033" title="BrandPL . Inhaled corticosteroids reduce growth. European Respiratory Journal2001;17(2):287‐94. ">Brand 2001</a>). A chronic disease such as asthma may lead to suppressed growth as children with asthma enter puberty at a later age (<a href="./references#CD010352-bbs2-0033" title="BrandPL . Inhaled corticosteroids reduce growth. European Respiratory Journal2001;17(2):287‐94. ">Brand 2001</a>). </p> </section> <section id="CD010352-sec-0033"> <h3 class="title" id="CD010352-sec-0033">How the intervention might work</h3> <p>The most widely available ICS are beclomethasone dipropionate (BDP), budesonide and fluticasone propionate. Chlorofluorocarbon‐BDP and budesonide are considered equipotent; fluticasone is considered twice as potent compared to chlorofluorocarbon‐BDP and budesonide. Additionally fluticasone and hydrofluoroalkane‐BDP are regarded as equipotent to ciclesonide and the recommended dosage of the Global Initiative for Asthma (GINA), Global Strategy for Asthma Management and Prevention 2011 guideline, is based on this equipotency (<a href="./references#CD010352-bbs2-0042" title="Global Initiative for Asthma(GINA) . Global Strategy for Asthma Management and Prevention, 2011. www.ginasthma.com. (accessed 14 December 2012). ">GINA 2011</a>). Almost all ICS are registered for twice‐daily use, except for budesonide, which is also registered for once‐daily use. No consistent significant or clinically relevant differences in effectiveness among available ICS have been identified (<a href="./references#CD010352-bbs2-0031" title="AdamsN , LassersonTJ , CatesCJ , JonesPW . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4] ">Adams 2007</a>). One systematic review comparing ICS with small particles (HFA‐BDP) with fluticasone showed no significant difference on forced expiratory volume in one second (FEV<sub>1</sub>) and peak expiratory flow (PEF) at a dose ratio of 1:1 (<a href="./references#CD010352-bbs2-0049" title="LassersonTJ , CatesCJ , JonesAB , LassersonEH , WhiteJ . Fluticasone versus HFA‐beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005309.pub3] ">Lasserson 2006</a>). There are concerns about adrenal suppression with fluticasone given to children at doses greater than 400 μg/day (<a href="./references#CD010352-bbs2-0031" title="AdamsN , LassersonTJ , CatesCJ , JonesPW . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4] ">Adams 2007</a>; <a href="./references#CD010352-bbs2-0053" title="MasoliM , FabianD , HoltS , BeasleyR . Developed for Global Initiative for Asthma (GINA). Allergy2004;59:469‐78. [Full report available on www.ginasthma.com] ">Masoli 2004</a>). Studies reporting on cases of acute adrenal insufficiency in children are almost invariably in children receiving fluticasone and not beclomethasone or budesonide (<a href="./references#CD010352-bbs2-0039" title="EijkemansM , OttenenBJ , YntemaJB . Adrenal cortex insufficiency in children due to inhaled corticosteroids. Nederlands tijdschrift voor Geneeskunde2011;155:A2862. ">Eijkemans 2011</a>; <a href="./references#CD010352-bbs2-0061" title="ToddGRG , AceriniCL , Ross‐RussellR , ZahraS , WarnerJT , McCanceD . Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Archives of Disease in Childhood2002;87:457‐61. ">Todd 2002</a>). In addition, children receiving fluticasone at half the daily dose of budesonide or beclomethasone appear to have a higher risk of pharyngitis (<a href="./references#CD010352-bbs2-0031" title="AdamsN , LassersonTJ , CatesCJ , JonesPW . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4] ">Adams 2007</a>). </p> <p>Ciclesonide is a relatively new drug with several potential advantages over the currently used ICS. It is inhaled as a pro‐drug, which is converted in the airways to an active metabolite (des‐ciclesonide) and therefore with potentially less local and systemic side effects. As both ciclesonide and its active metabolite des‐ciclesonide are highly protein bound (˜ 99%), this results in a low proportion of free, unbound drug in the circulation. The 100‐fold greater glucocorticoid receptor binding affinity of des‐ciclesonide compared to ciclesonide may be the explanation for the prolonged local anti‐inflammatory action in the lung and its clinical efficacy with once‐daily dosing. Because of extensive first‐pass metabolism, the systemic availability of des‐ciclesonide is less than 1%. For a detailed overview we refer to paper published by Dahl (<a href="./references#CD010352-bbs2-0037" title="DahlR . Ciclesonide for the treatment of asthma. Therapeutics and Clinical Risk Management2006;2(1):25‐37. ">Dahl 2006</a>). Furthermore, from a pressurised metered dose inhaler (pMDI), ciclesonide consists of small particles with a volume median diameter of 1.9 µm (compared to a volume median diameter of 3.5 µm for fluticasone, 2.8 µm for budesonide and 1.9 µm for HFA‐BDP) (<a href="./references#CD010352-bbs2-0038" title="deVriesTW , RottierBL , GjaltemaD , HagedoornP , FrijlinkHW , deBoerAH . Comparative in vitro evaluation of four corticosteroid metered dose inhalers: consistency of delivered dose and particle size distribution. Respiratory Medicine2009;103(8):1167‐73. ">De Vries 2009</a>). Because of smaller particle size and lower plume velocity, ciclesonide has a better delivery to the small airways and consequently, effective asthma control could be achieved at lower daily doses. </p> <p>Ciclesonide is registered for once‐daily use. Mean adherence rates may decline with increased frequency of dosing and therefore a once‐daily use could lead to better compliance compared to twice‐daily use (<a href="./references#CD010352-bbs2-0043" title="GuestJF , DavieAM , RuizFJ , GreenerMJ . Switching asthma patients to a once‐daily inhaled steroid improves compliance and reduces healthcare costs. Primary Care Respiratory Journal2005;14(2):88‐98. ">Guest 2005</a>; <a href="./references#CD010352-bbs2-0054" title="OsterbergL , BlaschkeT . Adherence to medication. New England Journal of Medicine2005;353(5):487‐97. ">Osterberg 2005</a>; <a href="./references#CD010352-bbs2-0056" title="PriceD , RobertsonA , BullenK , RandC , HorneR , StaudingerH . Improved adherence with once‐daily versus twice‐daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open‐label study. BMC Pulmonary Medicine2010;10:1. ">Price 2010</a>). Particularly in adolescents, adherence to treatment is a major problem. Ciclesonide has been approved in Europe for children 12 years of age and older. The drug is delivered by a metered dose inhaler (MDI) and registered for use with the AeroChamber Plus® spacer. </p> </section> <section id="CD010352-sec-0034"> <h3 class="title" id="CD010352-sec-0034">Why it is important to do this review</h3> <p>The Cochrane Airways Group decided to split the existing review entitled "Ciclesonide versus other inhaled steroids for chronic asthma" (<a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a>) into a review restricted to children and one restricted to adults. The effect of ciclesonide compared to placebo is subject of another Cochrane review (<a href="./references#CD010352-bbs2-0051" title="ManningPJ , GibsonPG , LassersonTJ . Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD006217] ">Manning 2008</a>).   </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010352-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010352-sec-0035"></div> <p>To assess the efficacy and adverse effects of ciclesonide compared to other ICS in the management of chronic asthma in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010352-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010352-sec-0036"></div> <section id="CD010352-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010352-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCT) comparing ciclesonide with another ICS. We included trials of parallel group design and cross‐over trials with a wash‐out period of two weeks or more. Available unpublished data were considered. </p> </section> <section id="CD010352-sec-0039"> <h4 class="title">Types of participants</h4> <p>Children (younger than 18 years) with physician‐diagnosed chronic asthma in all settings (general practice, outpatient departments, emergency departments and hospitalised) were eligible for inclusion. Trials that included children as well as adults (aged 18 years and older) were included provided that the data on children were reported separately. </p> <p>Studies with participants with pulmonary diagnosis other than asthma were excluded.</p> </section> <section id="CD010352-sec-0040"> <h4 class="title">Types of interventions</h4> <p>This review includes studies that have compared ciclesonide with other ICS at equivalent and lower doses of ciclesonide. The intervention period had to be at least four weeks. Concomitant therapies for asthma, such as short‐acting beta<sub>2</sub>‐agonists (rescue therapy), theophyllines, long‐acting beta<sub>2</sub>‐agonists (salmeterol or formoterol), and inhaled anticholinergics were permitted provided that the dose and type of drug remained stable and were the same in both groups and was not introduced at the start of the trial as part of the study protocol. Studies involving anti‐leukotrienes (e.g. singular, accolate), combination inhalers (fluticasone‐salmeterol and budesonide‐formoterol) or other airway anti‐inflammatory asthma therapy (e.g. cromones) were excluded. </p> </section> <section id="CD010352-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010352-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010352-list-0001"> <li> <p>Asthma symptoms: asthma symptom score and number of days without symptoms and use of rescue medication. </p> </li> <li> <p>(Severe) asthma exacerbations defined as:</p> <ul id="CD010352-list-0002"> <li> <p>hospital admission;</p> </li> <li> <p>visit to emergency department;</p> </li> <li> <p>need for additional course of corticosteroids;</p> </li> <li> <p>a combination of the above.</p> </li> </ul> </li> <li> <p>Adverse effects: oropharyngeal candidiasis, sore throat, symptoms of hoarseness, growth, lower‐leg growth, adrenal insufficiency, plasma cortisol, urinary cortisol excretion. </p> </li> </ol> </p> </section> <section id="CD010352-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010352-list-0003"> <li> <p>Quality of life.</p> </li> <li> <p>Compliance.</p> </li> <li> <p>Change in lung function (FEV<sub>1</sub>, Mid expiratory flow 25‐75%)  </p> </li> <li> <p>Airway inflammation assessed by biopsy, lavage or exhaled nitric oxide (fraction of nitric oxide in exhaled air (FeNO)) </p> </li> </ol> </p> </section> </section> </section> <section id="CD010352-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010352-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified from the Cochrane Airways Group (CAG) Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD010352-sec-0094">Appendix 1</a> for further details). We searched records in the Specialised Register coded as 'asthma' using the following terms: </p> <p>ciclesonide* or Alveso* or pregnenedione* or CIC</p> <p>We searched the CAG trials register from June 2007 up to November 2012. Additional searches in MEDLINE and EMBASE were undertaken using the strategies in <a href="./appendices#CD010352-sec-0100">Appendix 2</a> for articles published more recently (2007 to 2012). </p> </section> <section id="CD010352-sec-0046"> <h4 class="title">Searching other resources</h4> <p>Included and excluded studies of the earlier review that included adults as well as children (<a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a>) were checked if data concerning children were reported separately. Reference lists of all primary studies and review articles were reviewed for additional references. The manufacturer of ciclesonide (ALTANA Pharma and Nycomed) and authors of identified trials were contacted and asked to identify other published and unpublished studies. </p> <p>We searched <a href="http://www.clinicalstudyresults.org" target="_blank">www.clinicalstudyresults.org</a> for trial reports of CIC (December 2011). </p> </section> </section> <section id="CD010352-sec-0047"> <h3 class="title" id="CD010352-sec-0047">Data collection and analysis</h3> <section id="CD010352-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NB and BLR) screened the title and abstract of each citation identified for eligibility. Articles that appeared to meet the inclusion criteria were retrieved in full text. Published abstracts of trials and trials published in a language other than English were also included. Then, based on the full text of the articles, NB and BLR independently established whether each study met the inclusion criteria of the review. Disagreement was solved by discussion. </p> </section> <section id="CD010352-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted the data from the included studies independently of each other. We attempted to contact study authors to identify additional papers, confirm data for accuracy and completeness. </p> <p>We extracted data concerning the following characteristics of the included studies: study design; patient characteristics such as age, gender, asthma severity, inclusion and exclusion criteria, setting; diagnosis and diagnostic criteria used; characteristics of the interventions such as ICS type, dose, duration of study, method of delivery (MDI with or without spacer, breath actuated inhaler (BAI) or dry powder inhaler (DPI)); inhalation technique (breath hold after inhalation from DPI or BAI, inhalation from spacer with single breath followed by breath hold or tidal breathing) and reported outcome measures. </p> </section> <section id="CD010352-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Risk of bias of the included studies was independently assessed by two review authors according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010352-bbs2-0045" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Disagreement was solved by discussion. The following items were assessed: </p> <p> <ol id="CD010352-list-0004"> <li> <p>adequate sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (patient reported/subjective outcomes: asthma symptoms, adverse effects, quality of life, compliance); </p> </li> <li> <p>blinding (other outcomes);</p> </li> <li> <p>incomplete outcome data addressed (patient reported/subjective outcomes: asthma symptoms, adverse effects, quality of life, compliance); </p> </li> <li> <p>incomplete outcome data addressed (other outcomes);</p> </li> <li> <p>free of selective reporting;</p> </li> <li> <p>free of other bias? (e.g. baseline differences).</p> </li> </ol> </p> </section> <section id="CD010352-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>A mean difference (MD) and 95% confidence interval (CI) was calculated for continuous variables measured on identical metrics. A standardised mean difference (SMD) was used for the continuous variables that addressed the same type of outcome, but were measured on different scales. </p> <p>For dichotomous outcomes, we calculated a risk ratio (RR).</p> </section> <section id="CD010352-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the patient.</p> </section> <section id="CD010352-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of trials in which relevant data or information was missing that was needed for data synthesis and analyses. </p> </section> <section id="CD010352-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was assessed by comparing clinical characteristics of the included studies such as type of patients (age, gender, asthma severity, etc.), intervention (dose, inhalation technique, duration, etc.), comparison and outcome measures. Clinical homogeneity was discussed by the authors of this review and included experts in the field. Based on this discussion we decided whether pooling of results was sensible. Statistical heterogeneity was first assessed by visual inspection of the forest plots. We also applied the Chi<sup>2</sup> test for homogeneity and we calculated the I<sup>2</sup> statistic. To increase the power of the test for homogeneity we used a P &lt; 0.1 for rejecting the null‐hypothesis of homogeneity. Interpretation of the statistical heterogeneity was according to the recommendation of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010352-bbs2-0046" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>) and was as follows: </p> <p> <ul id="CD010352-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When interpreting the results of the test for homogeneity and the I<sup>2</sup> statistic, we took into account the size of the studies that were included in the meta‐analysis. </p> </section> <section id="CD010352-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to visually inspect funnel plots to assess reporting bias if we had been able to combine 10 or more trials in a forest plot. </p> </section> <section id="CD010352-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We only considered data of clinically homogeneous studies eligible to be combined. We hypothesised that the individual studies that evaluated the effect of ciclesonide estimated a common effect and therefore we chose to combine the results using a fixed‐effect model. If statistical heterogeneity was observed (Chi<sup>2</sup>: P &lt; 0.1 and I<sup>2</sup> &gt; 30%) a sensitivity analysis using a random‐effects model was applied, to determine whether variation between the studies affected the pooled estimate. Furthermore, evidence of statistical heterogeneity prompted exploration of factors that can explain heterogeneity such as clinical or methodological characteristics of studies. </p> <section id="CD010352-sec-0057"> <h5 class="title">Summary of findings table</h5> <p>We created 'Summary of findings' (SoF) tables for each comparison and primary outcomes. We used GRADE‐profiler software to generate SoF tables that included the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the overall quality of evidence on relevant (primary) outcomes (asthma symptoms, exacerbations and adverse effects) (<a href="./references#CD010352-bbs2-0057" title="SchunemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011a</a>; <a href="./references#CD010352-bbs2-0058" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011b</a>). Two review authors (SK and NB) independently graded the body of evidence. According to GRADE, RCTs start as high‐quality evidence. There are five reasons for downgrading the quality of a body of evidence for a specific outcome: limitations in design, indirectness of evidence, inconsistency, imprecision of results and high probability of publication bias. All these items were scored and reasons for downgrading were explicitly stated. Overall quality of evidence was graded 'high', 'moderate' or 'low' based on the likelihood of further research changing our confidence in the estimate of effect. We resolved discrepancies by consensus among two review authors (SK and NB). </p> </section> </section> <section id="CD010352-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses, provided we had sufficient data, according to age (&lt; six years and ≥ six years), asthma severity, dose of ciclesonide and delivery device (identical or different devices used for ciclesonide and BDP/budesonide/fluticasone) as well as inhalation manoeuvre. </p> </section> <section id="CD010352-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were planned to test the robustness of the results based on the results of the 'Risk of bias' assessment, provided we had sufficient data. We planned to repeat analyses with studies that scored a low risk of bias for allocation concealment, blinding (outcome: asthma symptoms, adverse effects, quality of life, compliance) or incomplete follow‐up (outcome: asthma symptoms, adverse effects, quality of life, compliance). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010352-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010352-sec-0060"></div> <section id="CD010352-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD010352-sec-0062"> <h4 class="title">Results of the search</h4> <p>Of the included and excluded studies of the existing Cochrane review of <a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a> three studies met our inclusion criteria (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). The updated search yielded 296 citations and an additional search of the website <a href="http://www.clinicalstudyresults.org" target="_blank">www.clinicalstudyresults.org</a> yielded 22 references. After screening of title and abstracts, the full text of 24 studies was assessed. Two reports identified by the search of <a href="http://www.clinicalstudy.org" target="_blank">www.clinicalstudy.org</a> were reports of studies identified in the search of the databases (<a href="./references#CD010352-bbs2-0008" title="AgertoftL , PedersenS . Inhaled ciclesonide does not affect lower leg growth rate or HPA‐axis function in children with mild asthma. European Respiratory Journal2004;24(Suppl 48):377s. AgertoftL , PedersenS . Lower‐leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatric Allergy and Immunology2010;21(1 pt 2):e199‐e205. AgertoftL , PedersenS . Short‐term lower‐leg growth rate and urine cortisol excretion in children treated with ciclesonide. Journal of Allergy and Clinical Immunology2005;115(5):940‐5. AgertorftL , PedersenS . Lower‐leg growth rate and APA‐axis function in children with asthma during treatment with inhaled ciclesonide. Journal of Allergy and Clinical Immunology2004;113(2 Suppl):S119. ">Agertoft 2010</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Of all identified studies, one study published in full text (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) and two studies published as abstracts (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>) met our inclusion criteria. Therefore, a total of six studies were included into this review. An overview of the selection process is shown in <a href="#CD010352-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010352-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010352-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In the previous review, four of the 13 ongoing studies were identified that potentially met our inclusion criteria. To date, three studies have been completed. One study was published but did not separately describe the data of children younger than 18 years of age (<a href="./references#CD010352-bbs2-0026" title="PostmaDS , O'ByrnePM , PedersenS . Comparison of the effect of low‐dose ciclesonide and fixed‐dose fluticasone propionate and salmeterol combination on long‐term asthma control. Chest2011;139(2):311‐8. ">Postma 2011</a>) and one study only including adults was excluded (<a href="./references#CD010352-bbs2-0029" title="van denBergeM , ArshadSH , IndPW , MagnussenH , HamelmannE , KanniessF , et al. Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering. Respiratory Medicine2009;103:1216‐23. ">van den Berge 2009</a>). One study is awaiting classification since no full reports were available of the study data (see <a href="./references#CD010352-sec-0112" title="">Characteristics of studies awaiting classification</a> table). One study originally found in the National Research Register record could not be found in the registers archives, and contact details of the author were no longer up to date (GIWA 2003). No references were found to published data of this study and therefore this study is regarded as obsolete. </p> <p>To retrieve additional data we contacted all contact authors of the included studies. Two of them replied and re‐directed us to the pharmaceutical companies involved. We did not get a reply from the companies on our request for additional data. </p> </section> <section id="CD010352-sec-0063"> <h4 class="title">Included studies</h4> <p>The characteristics of the six included studies are presented in the <a href="./references#CD010352-sec-0110" title="">Characteristics of included studies</a> table. </p> <p>Two studies were described as randomised double‐blind parallel group designs (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>) and four studies as randomised double‐blind double‐dummy parallel group designs (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). All were designed as non‐inferiority studies on lung function. </p> <p>The six studies randomised 3256 children with asthma and included children between the age of 4 and 17 years. One study did not specify how asthma was diagnosed (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>), whereas the other studies diagnosed asthma according to either the guidelines of the American Thoracic Society (ATS) (<a href="./references#CD010352-bbs2-0032" title="American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease1987;136(1):225‐44. ">American Thoracic Society 1987</a>) or the <a href="./references#CD010352-bbs2-0041" title="Global Initiative for Asthma (GINA) National Institutes of Health (NIH), National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention, 2003. www.ginasthma.org/Guidelines/guidelines‐archived‐2003‐update‐workshop‐report.html. (accessed 14 December 2012). ">GINA 2003</a> classification (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). There was insufficient information on how asthma was diagnosed in two studies (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). The children in the fully published studies had suffered from asthma for at least six months. </p> <p>In the six included studies, two different comparisons were assessed. Ciclesonide was compared to budesonide (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>) or fluticasone (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>; <a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) (see <a href="#CD010352-tbl-0004">Table 1</a>). All treatment periods were 12 weeks and outcomes were measured before and after the intervention period. The dose and delivery of the interventions varied between studies (see <a href="#CD010352-tbl-0004">Table 1</a>). Ciclesonide was delivered via MDIs in all studies. </p> <div class="table" id="CD010352-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the interventions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide dose</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inhalation technique</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Ciclesonide versus budesonide</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD (ex‐actuator; equivalent to 200 μg ex‐valve) 2 x 80 μg puffs in the evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 400 μg OD 2 x 200 μg puffs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide: HFA‐MDI with an AeroChamber®;</p> <p>Budesonide: Turbohaler®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 μg OD (ex‐actuator; equivalent to 2 puffs of 200 μg ex‐valve) 2 x 160 μg puffs administered in the evening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 800 μg OD (4 inhalations of <br/> 200 μg from the Turbohaler® device), administered in the evening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide: HFA‐MDI without spacer Budesonide: Turbohaler®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Ciclesonide versus fluticasone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDI with spacer, AeroChamber Plus®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 μg BID (ex‐actuator; equivalent to 100 μg BID ex‐valve)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID (ex‐actuator dose, equivalent to 100 μg BID ex‐valve)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HFA‐MDI without spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate inhalation technique no details described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 or 160 μg OD (ex‐actuator; equivalent to 100 and 200 μg ex‐valve) administered in the evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID (176 ex‐actuator; equivalent to 100 μg BID ex‐valve) in the morning and evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HFA 134‐MDI without spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good inhalation technique, no details described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BID: twice daily; ex‐actuator: drugs that leaves the inhaler; ex‐valve: drugs that leaves the metering chamber valve; HFA‐MDI: hydrofluoroalkane‐propelled metered dose inhaler; ICS: inhaled corticosteroid; MDI: metered dose inhaler; OD: once daily. </p> </div> </div> <p>All studies assessed our primary outcome asthma symptoms. Five studies assessed exacerbations and one study did not address this outcome at all (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>). None of the studies specifically defined asthma exacerbations that conformed to our definition as hospital admissions or visits to an emergency department or additional course of corticosteroids and the description of exacerbation varied between studies. Four studies defined asthma exacerbations as increasing asthma symptoms requiring change or addition of patient's medication other than increasing rescue medication (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>) and in one of these studies the patients with exacerbations were withdrawn (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>) and in two studies no definitions of exacerbations were described. One study did not report adverse events (<a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). None of the studies reported on compliance. </p> <p>The four fully published studies were all supported or sponsored by the manufacturer of ciclesonide. In all studies at least one of the authors was an employee of the manufacturer that sponsored the study. </p> </section> <section id="CD010352-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded 21 records (see <a href="./references#CD010352-sec-0111" title="">Characteristics of excluded studies</a>). Two studies were excluded because the intervention period in these studies was two weeks (<a href="./references#CD010352-bbs2-0008" title="AgertoftL , PedersenS . Inhaled ciclesonide does not affect lower leg growth rate or HPA‐axis function in children with mild asthma. European Respiratory Journal2004;24(Suppl 48):377s. AgertoftL , PedersenS . Lower‐leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatric Allergy and Immunology2010;21(1 pt 2):e199‐e205. AgertoftL , PedersenS . Short‐term lower‐leg growth rate and urine cortisol excretion in children treated with ciclesonide. Journal of Allergy and Clinical Immunology2005;115(5):940‐5. AgertorftL , PedersenS . Lower‐leg growth rate and APA‐axis function in children with asthma during treatment with inhaled ciclesonide. Journal of Allergy and Clinical Immunology2004;113(2 Suppl):S119. ">Agertoft 2010</a>; <a href="./references#CD010352-bbs2-0022" title="MatsunagaK , KawayamaT , TodaR , ImamuraY , HoshinoT , AizawaH . Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics. Proceedings of the European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna; 1971. ">Matsunaga 2009</a>) and, therefore, did not met our criteria of at least four weeks. </p> </section> </section> <section id="CD010352-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of the included studies is summarised in <a href="#CD010352-fig-0002">Figure 2</a>. The risk of bias was unclear for the two studies that were published as conference abstracts as no information was available to make a definite judgement on the different items (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). Our judgements for the remaining four studies that were published in full text are discussed below per item. </p> <div class="figure" id="CD010352-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010352-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010352-sec-0066"> <h4 class="title">Allocation</h4> <p>The randomisation method was clearly described and adequate in three studies (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). One study did not provide sufficient information (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). No study described allocation concealment and therefore the risk of bias for this item was deemed unclear. </p> </section> <section id="CD010352-sec-0067"> <h4 class="title">Blinding</h4> <p>The four fully published studies were described as double‐blind and double‐dummy. Therefore, risk of bias was assessed as low for both subjective outcomes and other outcomes (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). </p> </section> <section id="CD010352-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Loss to follow‐up was reported in all four studies. In three studies, 4% of the randomised patients did not complete the study (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>), only one study gave a clear description of the number of patients per group and the reasons for loss to follow‐up (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). In one study, 8% of the patients randomised terminated the study prematurely. The number of patients per group was described; however, no reasons for loss to follow‐up were reported (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>). All studies described that an intention‐to‐treat (ITT) analysis was performed but no details of the analyses were provided and it was not specified which values were imputed in the analyses. Therefore, risk of bias for the items regarding incomplete outcome data were deemed unclear. Two of the four studies reported the number of patients that violated the study protocol (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). The percentage of patients that violated the study protocol was similar in the three different groups in the study of <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> (ciclesonide 80 μg = 6%; 160 μg = 7%; fluticasone 88 μg = 6%). In the study of <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a> the percentage of patients that violated the study protocol was also similar, 14% of the ITT population in both groups. Two studies did not provide detailed information on study protocol violations (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). </p> </section> <section id="CD010352-sec-0069"> <h4 class="title">Selective reporting</h4> <p>The four fully published studies all reported the outcomes that were specified in their method section (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>; <a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>; <a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). </p> </section> <section id="CD010352-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>None of the four studies showed any obvious baseline differences, therefore for all studies risk of other biases were rated low. </p> </section> </section> <section id="CD010352-sec-0071"> <h3 class="title" id="CD010352-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD010352-tbl-0001"><b>Summary of findings for the main comparison</b> Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</a>; <a href="./full#CD010352-tbl-0002"><b>Summary of findings 2</b> Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</a>; <a href="./full#CD010352-tbl-0003"><b>Summary of findings 3</b> Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</a> </p> <section id="CD010352-sec-0072"> <h4 class="title">Ciclesonide versus budesonide</h4> <p>Two studies assessed the effect of ciclesonide compared to budesonide both administered once daily at dose ratios of 1:2. The dose of both ciclesonide and budesonide in one study (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>) was twice the dose of the other study (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). Ciclesonide was delivered using a hydrofluoroalkane‐propelled metered dose inhaler (HFA‐MDI) with the AeroChamber® spacer in one study (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>) and without a spacer in the other study (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). In both studies, the comparator drug, budesonide, was deliver using a Turbohaler®. </p> <p>Both studies were designed to assess non‐inferiority of ciclesonide versus budesonide. One study used the per protocol (PP) population to test for non‐inferiority (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>) and one study based the primary analysis on the PP population and used the ITT population to confirm the results (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). One study set non‐inferiority limits for lung function outcomes (FEV<sub>1</sub>: ‐150 mL; forced vital capacity (FVC): ‐150 mL and PEF: ‐20 L/minute), percentage of days without asthma symptoms and rescue medication (‐8%) and quality of life measured with Standardized Pediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) scores (‐0.5%) (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). One study set the non‐inferiority acceptance limit for the outcome FEV<sub>1</sub> at ‐100 mL, using the lower limit of 95% CI for differences between treatment groups (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). The studies were considered to be clinically similar and therefore data were pooled when possible. The results are shown in <a href="#CD010352-tbl-0005">Table 2</a> (see <a href="./full#CD010352-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="table" id="CD010352-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Effect of the intervention: ciclesonide versus budesonide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD versus BUD 400 μg OD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 320 μg OD versus BUD 800 μg OD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> asthma symptom score (sum score)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD 0.01, 95% CI ‐0.14 to 0.16</p> <p>PP: MD 0.03, 95% CI ‐0.20 to 0.25</p> <p>Non‐inferiority acceptance limit = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (no CIs reported)</p> <p>ITT: CIC: ‐0.07; BUD: ‐0.14</p> <p>PP: CIC: ‐0.07; BUD: ‐0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> use of rescue medication (puff/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD 0.06 puffs/day, 95% CI ‐0.26 to 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> % of asthma symptom and rescue medication‐free days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: CIC: mean 73%; BUD: mean 70%</p> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP: CIC: median 84%; BUD: median 85%</p> <p>Lower limit of the between difference was ‐1.4% and above non‐inferiority limit of ‐8% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Exacerbations:</i> patients with exacerbations*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR 2.71, 95% CI 0.61 to 12.11; <a href="./references#CD010352-fig-0003" title="">Analysis 1.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR 1.69, 95% CI 0.36 to 8.00; <a href="./references#CD010352-fig-0003" title="">Analysis 1.1</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> patients with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were reported in 38% of patients in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR** 1.44, 95% CI 0.96 to 2.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> change in body height</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline (least square mean)</p> <p>CIC: 1.18 cm; BUD: 0.70 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> 24‐hour urine cortisol adjusted for creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: 2.99 nmol/mmol creatinine; P &lt; 0.0001, one‐sided (decrease greater in the BUD group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: significant difference between groups (lower level in BUD group)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Secondary outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PAQLQ(S)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD ‐0.11, 95% CI ‐0.12 to 0.10, one‐sided superiority; <a href="./references#CD010352-fig-0004" title="">Analysis 1.2</a> </p> <p>Non‐inferiority acceptance limits = not provided</p> <p>PP not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square mean) 0.01, 95% CI ‐0.14 to 0.16; <a href="./references#CD010352-fig-0004" title="">Analysis 1.2</a> </p> <p>Non‐inferiority acceptance limit = ‐0.5%</p> <p>PP results were similar</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PACQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD ‐0.08, 95% CI ‐0.27 to 0.11, one‐sided superiority</p> <p>Non‐inferiority acceptance limit not provided</p> <p>PP not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Compliance</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Lung function:</i> FEV<sub>1</sub> (L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.019 L, 95% CI ‐0.059 to 0.022; <a href="./references#CD010352-fig-0005" title="">Analysis 1.3</a> </p> <p>PP: MD (least square means) ‐0.034 L, 95% CI ‐75 to 10</p> <p>Non‐inferiority acceptance limit = ‐100 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.03 L, 95% ‐0.14 to 0.8; <a href="./references#CD010352-fig-0005" title="">Analysis 1.3</a> </p> <p>PP: MD (least square means) ‐0.02 L, 95% CI ‐0.13 to 0.1</p> <p>Non‐inferiority acceptance limit = ‐150 mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Airway inflammation</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>Not assessed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BUD: budesonide; CI: confidence interval; CIC: ciclesonide; ITT: intention to treat analysis; MD: mean difference; OD: once daily; PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; PP: per protocol; RR: risk ratio. </p> <p>* Exacerbations were defined as an increasing asthma symptoms requiring change or addition of patient's medication other than increasing rescue medication. </p> <p>** Adverse events that needed treatment, reported in over 2% of patients in CIC or BUD group of safety population (N = 403). </p> </div> </div> <section id="CD010352-sec-0073"> <h5 class="title">Primary outcomes</h5> <p>Two studies on 1024 children found no significant differences between the groups regarding the outcome asthma symptoms (symptom scores, asthma symptom and rescue medication‐free days) (see <a href="#CD010352-tbl-0005">Table 2</a>). Asthma symptom scores were assessed using 5‐point scales where a score of 0 represented no asthma symptoms and a score of 4 very bad symptoms, unable to carry out daily activities. One study reported asthma symptom scores as a median change from baseline, which indicates skewed data and therefore we did not perform a meta‐analysis for this outcome. </p> <p>Pooled data for exacerbations (as defined in the original studies) showed no significant difference between ciclesonide versus budesonide (RR 2.20, 95% CI 0.75 to 6.43; two studies; 1024 children) (<a href="./references#CD010352-fig-0003" title="">Analysis 1.1</a>). </p> <p>The occurrence of adverse effects was similar in both treatment groups in one study on 621 children. Pharyngitis was one of the most reported adverse effect (ciclesonide: 6.0%; budesonide: 6.8%) in this study (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). Adverse effects likely to be related to treatment were low in the study comparing ciclesonide 320 μg versus budesonide 800 μg; 0.7% and 0.8% for ciclesonide and budesonide, respectively. This study also reported treatment emergent adverse effects (including pharyngitis, asthma aggravated, nasopharyngitis, upper respiratory tract infections) that were reported in more than 2% of the patients per group in a safety population (N = 403) and found no difference between ciclesonide and budesonide (RR 1.44, 95% CI 0.96 to 2.18) (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). Pooling of data was not possible because definition of adverse effects were very different between the studies. </p> <p>One study reported the outcome changes in body height after 12 weeks of intervention. The measurements were taken only in some centres and selection criteria and procedures of the subgroup of patients was not described. Height was measured by stadiometry in 58 patients of the ciclesonide 160 μg group and 26 in the budesonide 400 μg group. The study reported that the increase in height was significantly bigger in the ciclesonide compared to the budesonide group (1.18 cm versus 0.70 cm, respectively) (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). </p> <p>In the study that compared ciclesonide 160 μg once daily versus budesonide 400 μg once daily, one patient in each treatment group terminated participation due to serious adverse effects, but the author did not specify the nature of these effects (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). </p> <p>Both studies (1024 children) reported that 24‐hour urine cortisol adjusted for creatinine levels showed a significant decrease in the budesonide group compared to the ciclesonide group, but no numerical data were reported. </p> </section> <section id="CD010352-sec-0074"> <h5 class="title">Secondary outcomes</h5> <p>Both studies measured quality of life on the PAQLQ(S). One study used the interview version (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>) and in the other study the PAQLQ(S) was self‐administered (<a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a>). Patients answered questions using a 7‐point scale where a score of 1 indicated maximum impairment and 7 indicated no impairment. Pooled results showed no significant differences between the groups (RR ‐0.00, 95% CI ‐0.09 to 0.09; two studies; 1010 children) (<a href="./references#CD010352-fig-0004" title="">Analysis 1.2</a>). One study on 621 children also assessed quality of life using the self‐administered Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ). Carers answered questions using a 7‐point scale, where a score of 1 indicated maximum impairment and 7 indicated no impairment, and reported one‐sided superiority of ciclesonide but did not provide acceptance limits (<a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a>). </p> <p>Pooled result of FEV<sub>1</sub> (higher scores indicates better lung function) showed no significant MD between groups (RR ‐0.02, 95% CI ‐0.10 to 0.05; two studies; 1021 children) (<a href="./references#CD010352-fig-0005" title="">Analysis 1.3</a>). </p> <p>Compliance and airway inflammation were not formally assessed in either of the studies comparing ciclesonide versus budesonide. </p> </section> </section> <section id="CD010352-sec-0075"> <h4 class="title">Ciclesonide versus fluticasone propionate</h4> <p>Four studies assessed the effect of ciclesonide versus fluticasone (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>; <a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) at a dose ratio of 1:1 and one study also assessed a dose ratio of 1:2 (ciclesonide 80 μg once daily compared to the fluticasone 88 μg twice daily; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Ciclesonide was administered once daily in all but one study that administered ciclesonide 80 μg twice a day (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>). One study did not report how either of the study drugs were delivered (<a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). In one study both ciclesonide and fluticasone were delivered using an MDI with the AeroChamber Plus® spacer (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>) and in the other two studies both drugs were delivered using an HFA‐MDI without a spacer (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Two studies were designed to assess non‐inferiority of ciclesonide. Both studies performed a PP analysis and used an ITT analysis to test for robustness of the results. In both studies, the non‐inferiority limits were set for the primary endpoint FEV<sub>1</sub> at ‐0.100 L (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). In the study by <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>, non‐inferiority limits were also set at 0.5 for PAQLQ(S) and PACQLQ scores; and +0.30 scores for asthma symptom score sum. </p> <p>Of the four studies that assessed a dose ratio of 1:1, the study that administered ciclesonide 80 μg twice daily (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>) was considered to be clinically similar to the studies that administered ciclesonide 160 μg once daily (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Therefore, we pooled the data of these studies where possible. The results are shown in <a href="#CD010352-tbl-0006">Table 3</a>. </p> <div class="table" id="CD010352-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects of the intervention: ciclesonide versus fluticasone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg BID vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg BID vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg OD vs. FP 88 μg BID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> asthma symptom score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT and PP:</p> <p>0.00, 95% CI ‐0.29 to 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>Unclear if ITT or PP *:</p> <p>0.07, 95% CI ‐0.14 to 0.28</p> <p>Non‐inferiority acceptance limit = 0.30 sum score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom score decreased and was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>Unclear if ITT or PP **:</p> <p>0.07, 95% CI ‐0.14 to 0.28</p> <p>Non‐inferiority acceptance limit = 0.30 sum score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> use of rescue medication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT and PP: 0.00, 95% CI ‐1.23 to 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (Hodges Lehmann point estimate)</p> <p>ITT: CIC: ‐1.13; FP: ‐1.29</p> <p>PP: CIC: ‐1.14; FP: ‐1.29</p> <p>All P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication decreased and was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (Hodges Lehmann point estimate)</p> <p>ITT: CIC: ‐1.20; FP: ‐1.29</p> <p>PP: CIC: ‐1.21; FP: ‐1.29</p> <p>All P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms: a</i> sthma symptom‐free days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT: ‐1.01, 95% CI ‐4.60 to 2.46</p> <p>PP: ‐1.01, 95% CI ‐4.82 to 2.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> % of asthma symptom and rescue medication‐free days combined</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage was high and did not differ significantly between the treatment groups (PP) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>CIC: 91.5%; FP: 94%</p> <p>P = 0.1320 (2‐sided between treatments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PP: mean percentage was high and did not differ between the treatment groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Exacerbations:</i> number of patients with exacerbations</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26, 95% CI 0.34 to 4.66; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45, 95% CI 0.47 to 4.49; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC: 2.3%; FP: 2.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.57, 95% CI 1.35 to 9.47; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> % of patients with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A similar percentage of patients reported adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88, 95% CI 0.72 to 1.07; <a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98, 95% CI 0.81 to 1.17; <a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> cortisol 24‐hour urine sample (nmol/mmol)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: difference between 2 groups was not statistically significant</p> <p>ITT and restricted ITT</p> <p>(which included only</p> <p>those urine cortisol</p> <p>measurements with a</p> <p>corresponding urine</p> <p>creatinine value within</p> <p>the normal range)</p> <p>A statistically significant</p> <p>difference in favour of CIC was seen in the restricted ITT analysis</p> <p>(P = 0.006). The findings were similar</p> <p>for patients who were ICS‐naive and patients who had received ICS prior to study entry</p> <p>although the differences were numerically greater in previously ICS‐naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety analysis**: MD</p> <p>0.54 nmol/mmol, 95% CI ‐5.92 to 7.00; <a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety analysis**: MD 1.15 nmol/mmol, 95% CI 0.07 to 2.23; <a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Secondary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PAQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed CIC 160 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = ‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed for CIC80 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = ‐0.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PACQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed CIC 160 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed for CIC80 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Compliance</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Change in lung function:</i> </b> </p> <p><b>FEV<sub>1</sub> (L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) 0.0 L, 95% CI ‐0.042 to 0.042; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) 0.001, 95% ‐0.044 to 0.046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.02 L, 95% CI ‐0.07 to 0.04; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) ‐0.026, 95% CI ‐0.086 to 0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement similar between groups no point estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement similar between groups no point estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.05 L, 95% CI ‐0.11 to 0.01; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) ‐0.056, 95% CI ‐0.12 to ‐0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Airway inflammation</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BID: twice daily; CI: confidence interval; CIC: ciclesonide; FP: fluticasone; ICS: inhaled corticosteroid; ITT: intention to treat analysis; OD: once daily; PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; PP: per protocol analysis. </p> <p>* = In this study analyses were based on PP population and analysis of ITT population was used to confirm results, description of the results are unclear but we assumed it to be based on analysis of PP population. </p> <p>** = safety analysis excluded patients with concurrent nasal, ophthalmological or dermatological corticosteroid treatment. </p> </div> </div> <section id="CD010352-sec-0076"> <h5 class="title">Primary outcomes</h5> <section id="CD010352-sec-0077"> <h6 class="title">Dose ratio 1:1</h6> <p>In two studies on 1048 children asthma symptom scores were assessed using a 5‐point scale where a score of 0 represented no asthma symptoms and a score of 4 represented very bad symptoms, unable to carry out daily activities (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). The results could not be pooled since data were reported as medians and this indicates skewed data. The other two studies on 932 children did not provide information on how asthma symptoms were measured (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>) (see: <a href="./full#CD010352-tbl-0002">summary of findings Table 2</a>). </p> <p>No significant differences were found in asthma symptoms and rescue medication‐free days (four studies; 1934 children) (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>; <a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) and non‐inferiority of ciclesonide was confirmed (limit was set at 0.3) for asthma symptom scores in one study on 492 children (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) (see <a href="#CD010352-tbl-0006">Table 3</a>). </p> <p>Pooled data of two studies comparing ciclesonide 160 μg versus fluticasone 88 μg twice daily showed no significant difference in number of patients with exacerbations (RR 1.37, 95% CI 0.58 to 3.21; two studies; 1003 children) (<a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a>) (<a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>; <a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). One study on 420 children reported that the number of patients with exacerbations was similar in both the ciclesonide and fluticasone groups (2.3% and 2.2%, respectively) (<a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). </p> <p>One study on 492 children reported that five (2.1%) children treated with ciclesonide 160 μg and two (0.8%) children treated with fluticasone 88 μg twice daily discontinued the study prematurely due to asthma exacerbation (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>No significant difference in number of patients with adverse events were found between ciclesonide 160 μg and fluticasone 88 μg twice daily (RR 0.88, 95% CI 0.72 to 1.07; one study; 492 children) (<a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a>) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). The other two studies on 1023 children reported that adverse effects were similar in both groups (<a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a>; <a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a>) and one study did not assess adverse effects (<a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a>). </p> <p>The outcome 24‐hour urine cortisol adjusted for creatinine levels was reported in one study. No significant differences were found for ciclesonide compared to fluticasone (MD 0.54 nmol/mmol, 95% CI ‐5.92 to 7.00; one study; 492 children) (<a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a>). </p> </section> <section id="CD010352-sec-0078"> <h6 class="title">Dose ratio 1:2</h6> <p>In one study on 502 children, no significant differences were found in asthma symptoms and rescue medication‐free days. For asthma symptom sum scores non‐inferiority (limit was set at 0.3) was confirmed (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>) </p> <p>The number of exacerbations was significantly higher in the ciclesonide 80 μg once‐daily group compared to the fluticasone 88 μg twice‐daily group (RR 3.57, 95% CI 1.35 to 9.47; one study; 502 children) (<a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a>) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>Thirteen (5.2%) participants treated with ciclesonide 80 μg and two (0.8%) treated with fluticasone 88 μg discontinued the study prematurely due to asthma exacerbation (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>No significant differences in number of patients with adverse effects were found between ciclesonide 80 μg once daily and fluticasone 88 μg twice daily (RR 0.98, 95% CI 0.81 to 1.1; one study; 502 children) (<a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a>) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>No significant difference was found for 24‐hour urine cortisol adjusted for creatinine levels in ciclesonide 80 μg once daily versus fluticasone 88 μg twice daily (MD 1.15 nmol/mmol, 95% CI 0.07 to 2.23; one study; 502 children) (<a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD010352-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD010352-sec-0080"> <h6 class="title">Dose ratio 1:1</h6> <p>Quality of life measured by the PAQLQ and the PACQLQ was reported in one study on 492 children (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Patients and carers answered questions using a 7‐point scale where a score of 1 indicated maximum impairment and 7 indicated no impairment. </p> <p>Non‐inferiority was confirmed for both measurements for ciclesonide compared to fluticasone (P &lt; 0.0001, one‐sided) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). Non‐inferiority limits were set at ‐0.5 for the PAQLQ scores and 15 for the PACQLQ scores. The other studies did not formally assess quality of life. </p> <p>Pooled data of two studies showed no significant difference in FEV<sub>1</sub> between ciclesonide 160 μg and fluticasone 88 μg (‐0.01 L, 95% CI ‐0.04 to 0.02; two studies; 1000 children) (<a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a>). </p> <p>None of the studies formally assessed outcomes on compliance or airway inflammation.</p> </section> <section id="CD010352-sec-0081"> <h6 class="title">Dose ratio 1:2</h6> <p>Quality of life was measured by the PAQLQ(S) and the PACQLQ. Patients and carers answered questions using a 7‐point scale where a score of 1 indicated maximum impairment and 7 indicated no impairment. Non‐inferiority of ciclesonide versus fluticasone was confirmed for both measurements (P &lt; 0.0001, one‐sided) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>Results were similar in both groups and non‐significant for FEV<sub>1</sub> (higher FEV<sub>1</sub> indicates better lung function) and non‐inferiority was confirmed (MD ‐0.05 L, 95% CI ‐0.11 to 0.01; one study; 499 children) (<a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a>) (limits set at ‐100 L) (<a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a>). </p> <p>The outcomes compliance or airway inflammation were not formally assessed.</p> <p>It was not possible to conduct subgroup or sensitivity analyses due to lack of sufficient data. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010352-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010352-sec-0082"></div> <section id="CD010352-sec-0083"> <h3 class="title" id="CD010352-sec-0083">Summary of main results</h3> <p>In this review we assessed the efficacy and safety of ciclesonide compared to other ICS (budesonide and fluticasone) at a dose ratio 1:1 and 1:2 in the treatment of children younger than 18 years of age with chronic asthma. We found six studies including 3256 children that met our inclusion criteria. </p> <p>We found no significant differences in efficacy between ciclesonide and fluticasone or budesonide for asthma symptoms and exacerbations after 12 weeks of treatment, except for one study comparing ciclesonide versus fluticasone (1:2) that found significantly more exacerbations in the ciclesonide group. Adherence was not assessed in the studies. </p> <p>With regards to safety, local side effects such as pharyngitis were seen in both treatment groups with no significant differences, even in the study using a very high dose of budesonide (800 μg) administered once daily. Looking at systemic side effects, one study showed a significant improvement in height in the ciclesonide group compared to the budesonide group after 12 weeks of intervention, but measurements were only performed in a subset of patients. Studies assessing 24‐hour urinary cortisol levels showed either less suppression (ciclesonide versus budesonide) or no significant difference (ciclesonide versus fluticasone). </p> </section> <section id="CD010352-sec-0084"> <h3 class="title" id="CD010352-sec-0084">Overall completeness and applicability of evidence</h3> <p>Only six studies fulfilled our inclusion criteria, of which two studies were only published in abstract form, with limited details available concerning the participants enrolled, definition of outcome measures and trial methodology. The studies were mainly performed in Eastern European countries and South‐Africa, where fewer children might have received ICS treatment before enrolment in the studies than in western European countries.  Patients included in the published studies were aged four to 15 years and diagnosed with chronic moderate‐to‐severe asthma according to ATS/GINA criteria, with a relatively poor FEV<sub>1</sub> as a requirement at study entry in most of the included studies. No studies comparing ciclesonide versus HFA‐BDP were found. Different doses of both ciclesonide and comparator ICS were used; ciclesonide 80 to 320 μg, budesonide 400 to 800 μg, and fluticasone 88 to 176 μg in a pMDI‐AeroChamber Plus® combination (fluticasone, ciclesonide), as a pMDI without a spacer (fluticasone, ciclesonide) or DPI (budesonide). Current evidence is insufficient to recommend the optimal doses of ICS. Studies comparing different ICS doses could not reveal a clear dose‐response relationship in terms of efficacy and safety in children with mild‐to‐moderate asthma (<a href="./references#CD010352-bbs2-0063" title="ZhangL , AxelssonI , ChungM , LauJ . Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics2011;127(1):129‐38. ">Zhang 2011</a>). However, all ICS doses in the studies were within accepted ranges for children. Fluticasone and ciclesonide are not registered with the AeroChamber Plus®; further, the use of a pMDI without a spacer is discouraged with children. Because all these different combinations were used, it is not known which part of the effect can be attributed to the ICS used and which part to the inhaler used and the conclusions are only valid for the chosen comparisons. </p> <p>In all studies for the outcome adverse effects, 24‐hour urinary cortisol levels was measured. The clinical relevance of lower 24‐hour urinary cortisol levels for patients and practitioners is unclear and more important is the ability of the adrenal cortex to be able to respond to stressful circumstances, such as an infection, fever, etc. The most appropriate test would then be the more invasive low‐dose adrenocorticotropic hormone (ACTH) (Synacthen) stimulation test, which is more sensitive in detecting adrenal impairment (<a href="./references#CD010352-bbs2-0036" title="CrowleyS , HindmarshPC , HolowniaP , HonourJW , BrookCG . The use of low doses of ACTH in the investigation of adrenal function in man. Journal of Endocrinology1991;130(3):475‐9. ">Crowley 1991</a>; <a href="./references#CD010352-bbs2-0050" title="LipworthBJ . Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta‐analysis. Archives of Internal Medicine1999;159(9):941‐55. ">Lipworth 1999</a>). However, for relevant systemic adverse effects, such as growth and adrenal insufficiency, a follow‐up period of 12 weeks is too short. </p> <p>One study was published assessing the long‐term safety of ciclesonide (<a href="./references#CD010352-bbs2-0059" title="SkonerDP , MasperoJ , BanerjiD . Assessment of the long‐term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics2008;121(1):e1‐14. ">Skoner 2008</a>). This RCT was not included in this review, because it compared ciclesonide to placebo. Mean linear growth velocity and 24‐hour urinary cortisol levels were similar in the three groups after one year. However, this study could not provide enough reassurance about safety, as considerable concern was expressed about compliance of the children as their asthma was very mild and the study failed to show any benefit of ciclesonide in terms of lung function or asthma control (<a href="./references#CD010352-bbs2-0035" title="ChapmanKR . Safer inhaled corticosteroid therapy for asthma. Pediatrics2008;121(1):179‐80. ">Chapman 2008</a>; <a href="./references#CD010352-bbs2-0021" title="MalozowskiS . Assessment of the long‐term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics2008;122(1):213. ">Malozowski 2008</a>).  </p> <p>All studies included in this review were designed as non‐inferiority trials. The allowance of setting pre‐defined non‐inferiority acceptance limits the concern is that drugs that are less effective will be classified as non‐inferior or as effective as the control drug. A trial showing non‐inferiority of the experimental drug suggests that the experimental drug is as good as the standard treatment. However, the width of the pre‐defined margins of inferiority has to be taken into account when interpreting the results of these trials individually. Wide margins can result in concluding that the experimental treatment is equally beneficial when it is really less beneficial. Additionally, non‐inferiority should be assessed for relevant outcomes, with a sufficiently long treatment and follow‐up period.  </p> <p>Not all of the included studies in our review provided non‐inferiority acceptance limits for our primary outcomes. Additionally most of the non‐inferiority limits were hard to interpret for reasons such as unclear description of the outcome measure (asthma symptom scores) and no information available on clinical important difference of the questionnaire (PACQLQ). To help readers of this review interpret data of individual studies we provided pre‐defined non‐inferiority limits where possible. </p> <p>The results of the primary studies are focused on non‐inferiority of ciclesonide versus another ICS. However, when data could be pooled non‐inferiority was not a concern anymore since the point estimate and CI are not influenced by the acceptance limits set in the individual studies. In addition, a meta‐analysis of non‐inferiority studies showed that drugs that were found non‐inferior in published RCTs were not shown to be systematically less effective than standard treatments (<a href="./references#CD010352-bbs2-0060" title="SoonawalaD , MiddelburgRA , EggerM , VandenbrouckeJP , DekkersOM . Efficacy of experimental treatments compared with standard treatments in non‐inferiority trials: a meta‐analysis of randomized controlled trials. International Journal of Epidemiology2010;39:1567‐81. ">Soonawala 2010</a>). </p> </section> <section id="CD010352-sec-0085"> <h3 class="title" id="CD010352-sec-0085">Quality of the evidence</h3> <p>Using recommendations in the Cochrane Handbook and from the GRADE working group, we judged that the quality of the evidence was 'low' for the outcomes asthma symptoms and adverse events and 'very low' for the outcome exacerbations for ciclesonide versus budesonide (dose ratio 1:1; Summary of findings table 1). The quality of evidence was graded 'moderate for the outcome asthma symptoms, 'very low' for the outcome exacerbations and 'low' for the outcome adverse events for ciclesonide versus fluticasone (dose ratio 1:1; Summary of findings table 2). For ciclesonide versus fluticasone (dose ratio 1:2) the quality was rated 'low' for the outcome asthma symptoms and 'very low' for exacerbations and adverse events (dose ratio 1:2; Summary of findings table 3). </p> <p>The evidence was regarded TO BE indirect due to the fact that in all studies the outcomes were measured after a 12‐week intervention period, which was regarded as an insufficient period to expect an effect on the outcomes adverse events and exacerbations. </p> </section> <section id="CD010352-sec-0086"> <h3 class="title" id="CD010352-sec-0086">Potential biases in the review process</h3> <p>We used the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010352-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>) to prevent or restrict the risk of bias in our review process. A comprehensive search of the literature searching several databases was conducted. We are confident that all relevant published studies for this review were found. We did attempt to find study protocols by searching <a href="http://www.clinicalstudyresults.org" target="_blank">www.clinicalstudyresults.org</a>. We included six studies and therefore we could not generate funnel plots to identify publication bias. We contacted study authors in an attempt to find additional data, but did not receive any. Two review authors independently performed study selection, data collection, risk of bias and GRADE assessment to minimise bias. We did not write a protocol for this review but used the protocol of the review of <a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a>. Any changes to this protocol are listed in the following section of this review (<a href="#CD010352-sec-0108">Differences between protocol and review</a>). </p> </section> <section id="CD010352-sec-0087"> <h3 class="title" id="CD010352-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are largely in keeping with other reviews on small particle size and reviews in adult patients. The systematic review by <a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a> comparing ciclesonide to other ICS in adults reached the same conclusions on efficacy outcomes; ciclesonide is equal to budesonide/fluticasone in terms of lung function end points, but for our primary outcomes this could not be established due to wide CIs (<a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a>). The results of this review are also similar to the reported results on the outcomes FEV<sub>1</sub> and quality of life in a narrative review that discusses ciclesonide as a treatment for asthma in adults and children (<a href="./references#CD010352-bbs2-0037" title="DahlR . Ciclesonide for the treatment of asthma. Therapeutics and Clinical Risk Management2006;2(1):25‐37. ">Dahl 2006</a>). In this narrative review, the authors reported that in children the efficacy of ciclesonide was equivalent to fluticasone for the outcomes FEV<sub>1</sub> and quality of life (<a href="./references#CD010352-bbs2-0037" title="DahlR . Ciclesonide for the treatment of asthma. Therapeutics and Clinical Risk Management2006;2(1):25‐37. ">Dahl 2006</a>). A contrast with <a href="./references#CD010352-bbs2-0052" title="ManningP , GibsonPG , LassersonTJ . Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007031] ">Manning 2009</a> and <a href="./references#CD010352-bbs2-0037" title="DahlR . Ciclesonide for the treatment of asthma. Therapeutics and Clinical Risk Management2006;2(1):25‐37. ">Dahl 2006</a> was the lower oral candidiasis with ciclesonide compared to fluticasone in adults, which we did not find in children. Other reviews comparing small‐particle‐size ICS with normal‐particle‐size ICS so far could not identify improved efficacy or safety on relevant end points compared to normal‐particle‐size ICS (<a href="./references#CD010352-bbs2-0031" title="AdamsN , LassersonTJ , CatesCJ , JonesPW . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4] ">Adams 2007</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010352-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010352-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010352-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 1 Patients with exacerbations." data-id="CD010352-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 1 Patients with exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 2 Quality of life PAQLQ (S)." data-id="CD010352-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 2 Quality of life PAQLQ (S). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 3 FEV1 least square means (L)." data-id="CD010352-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ciclesonide versus budesonide (dose ratio 1:2), Outcome 3 FEV<sub>1</sub> least square means (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ciclesonide versus fluticasone, Outcome 1 Patients with exacerbations." data-id="CD010352-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Ciclesonide versus fluticasone, Outcome 1 Patients with exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ciclesonide versus fluticasone, Outcome 2 Adverse events: number of patients with adverse events." data-id="CD010352-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Ciclesonide versus fluticasone, Outcome 2 Adverse events: number of patients with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ciclesonide versus fluticasone, Outcome 3 Adverse events: 24‐ hour urine free cortisol adjusted for creatinine (nmol/mmol)." data-id="CD010352-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Ciclesonide versus fluticasone, Outcome 3 Adverse events: 24‐ hour urine free cortisol adjusted for creatinine (nmol/mmol). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010352-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/urn:x-wiley:14651858:media:CD010352:CD010352-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_t/tCD010352-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ciclesonide versus fluticasone, Outcome 4 Generic FEV1 least square mean (L)." data-id="CD010352-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Ciclesonide versus fluticasone, Outcome 4 Generic FEV<sub>1</sub> least square mean (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010352/media/CDSR/CD010352/image_n/nCD010352-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010352-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> budesonide (dose ratio 1:2) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide (dose ratio 1:2)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies used a 5‐point scale, but insufficient data were reported to allow meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (9 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.2</b> <br/> (0.75 to 6.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1024 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data could not be meta‐analysed because the definitions of adverse events were too diverse </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> In one study the dose of budesonide was much higher than what is commonly prescribed in clinical practice. <br/> <sup>2</sup> Both studies were sponsored by the manufacturer and at least one of the authors of each study was an employee of the manufacturer that sponsored the study. <br/> <sup>3</sup> The intervention period of 12 weeks was too short to expect any major changes in this outcome. <br/> <sup>4</sup> Confidence intervals of estimated effect include no effect and exceed a relative reduction or increase risk of 25%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ciclesonide versus budesonide (dose ratio 1:2) for chronic asthma in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010352-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> fluticasone (dose ratio 1:1) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone (dose ratio 1:1)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1468 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies used a 5‐point scale and 1 study did not provide details how asthma symptoms were measured. Data could not be pooled due to diversity in scales </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (10 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.37</b> <br/> (0.58 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1003 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1560 <br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were defined differently across studies therefore results could not be pooled </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Two fully published studies were sponsored by the manufacturer and at least one of the authors of each study was an employee of the manufacturer that sponsored the study. <br/> <sup>2</sup> The intervention period of 12 weeks is too short to expect any major changes in this outcome. <br/> <sup>3</sup> Confidence intervals of estimated effect include no effect and exceed a relative reduction or increase risk of 25%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:1) for chronic asthma in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010352-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic asthma in children <br/> <b>Settings:</b> all settings <br/> <b>Intervention:</b> ciclesonide <br/> <b>Comparison:</b> fluticasone (dose ratio 1:2) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone (dose ratio 1:2)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptom</b> <br/> Asthma symptom score (scale 0 to 4) <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean asthma symptom in the control groups was <br/> <b>1.33</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean asthma symptom in the intervention groups was <br/> <b>0.07 higher</b> <br/> (0.14 to 0.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>482 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estimates are medians indicating data was skewed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations</b> <br/> Number of patients with exacerbations <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (27 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.48</b> <br/> (1.35 to 8.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Number of patients with adverse events <br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>476 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> <br/> (424 to 514) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.89 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Based on one study that was underpowered for a non‐inferiority trial. <br/> <sup>2</sup> The study was sponsored by the manufacturer and at least one author was an employee of the manufacturer that sponsored the study. <br/> <sup>3</sup> The intervention period of 12 weeks is too short to expect any major changes in this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ciclesonide versus fluticasone (dose ratio 1:2) for chronic asthma in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010352-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the interventions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ciclesonide dose</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Application</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inhalation technique</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Ciclesonide versus budesonide</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD (ex‐actuator; equivalent to 200 μg ex‐valve) 2 x 80 μg puffs in the evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 400 μg OD 2 x 200 μg puffs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide: HFA‐MDI with an AeroChamber®;</p> <p>Budesonide: Turbohaler®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 μg OD (ex‐actuator; equivalent to 2 puffs of 200 μg ex‐valve) 2 x 160 μg puffs administered in the evening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide 800 μg OD (4 inhalations of <br/> 200 μg from the Turbohaler® device), administered in the evening </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciclesonide: HFA‐MDI without spacer Budesonide: Turbohaler®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>Ciclesonide versus fluticasone</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDI with spacer, AeroChamber Plus®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 μg OD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 μg BID (ex‐actuator; equivalent to 100 μg BID ex‐valve)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID (ex‐actuator dose, equivalent to 100 μg BID ex‐valve)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HFA‐MDI without spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate inhalation technique no details described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 or 160 μg OD (ex‐actuator; equivalent to 100 and 200 μg ex‐valve) administered in the evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluticasone 88 μg BID (176 ex‐actuator; equivalent to 100 μg BID ex‐valve) in the morning and evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HFA 134‐MDI without spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Good inhalation technique, no details described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BID: twice daily; ex‐actuator: drugs that leaves the inhaler; ex‐valve: drugs that leaves the metering chamber valve; HFA‐MDI: hydrofluoroalkane‐propelled metered dose inhaler; ICS: inhaled corticosteroid; MDI: metered dose inhaler; OD: once daily. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010352-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Effect of the intervention: ciclesonide versus budesonide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD versus BUD 400 μg OD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 320 μg OD versus BUD 800 μg OD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0006" title="vonBergA , EngelstatterR , MinicP , SreckovicM , Garcia‐GarciaML , LatosT , et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily versus budesonide 400 microg once daily in children with asthma. Pediatric Allergy and Immunology2007;18(5):391‐400. vonBergA , Garcia‐GarciaML , HerllbardtS , BethkeTD . Ciclesonide 160 ug once daily is as effective as budesonide 400 ug once daily in pediatric patients with persistent asthma. Journal of Allergy and Clinical Immunology2006;117(2 Suppl 1):s11. vonBergA , MinicP , SreckovicM , BollrothC , HellbardtS , EngelstätterR . Efficacy and safety of once‐daily ciclesonide 160 µg as compared with once‐daily budesonide 400 µg in paediatric asthma patients. Thorax2005;2(Suppl II):ii43. vonBergA , VermeulenJ , ManjraA , WeberH , HellbardtS , EngelstätterR . Once‐daily ciclesonide 160 mcg is as effective as once‐daily budesonide 400 mcg in improving lung function in children with asthma and demonstrates a favorable safety profile. Paediatric Respiratory Reviews2006;7:s283‐4. vonBergA , VermeulenJH , ZachgoW , HellbardtS , BethkeTD , EngelstätterR . Comparison of ciclesonide 160 mcg/d with budesonide 400 mcg/d in a randomised, double‐blind study in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">von Berg 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0005" title="VermeulenJH , GyurkovitsK , RauerH , EngelstätterR . Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine2007;101(10):2182‐91. VermeulenJH , KósaL , VillaJR , RauerH , WurstW , EngelstätterR . Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide. European Respiratory Journal2006;28(Suppl 50):206s. VermeulenJH , MinicP , BarkaiL , SreckovicMD , GyurkovitisK , RauerH , et al. Ciclesonide 320 mcg once daily is as effective as budesonide 800 mcg once daily and has a favourable safety profile in adolescent patients with persistent asthma. Proceedings of the American Thoracic Society International Conference; 2006 May 19‐24; San Diego. ">Vermeulen 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> asthma symptom score (sum score)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD 0.01, 95% CI ‐0.14 to 0.16</p> <p>PP: MD 0.03, 95% CI ‐0.20 to 0.25</p> <p>Non‐inferiority acceptance limit = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (no CIs reported)</p> <p>ITT: CIC: ‐0.07; BUD: ‐0.14</p> <p>PP: CIC: ‐0.07; BUD: ‐0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> use of rescue medication (puff/day)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD 0.06 puffs/day, 95% CI ‐0.26 to 0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> % of asthma symptom and rescue medication‐free days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: CIC: mean 73%; BUD: mean 70%</p> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP: CIC: median 84%; BUD: median 85%</p> <p>Lower limit of the between difference was ‐1.4% and above non‐inferiority limit of ‐8% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Exacerbations:</i> patients with exacerbations*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR 2.71, 95% CI 0.61 to 12.11; <a href="./references#CD010352-fig-0003" title="">Analysis 1.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR 1.69, 95% CI 0.36 to 8.00; <a href="./references#CD010352-fig-0003" title="">Analysis 1.1</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> patients with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were reported in 38% of patients in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: RR** 1.44, 95% CI 0.96 to 2.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> change in body height</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline (least square mean)</p> <p>CIC: 1.18 cm; BUD: 0.70 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> 24‐hour urine cortisol adjusted for creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: 2.99 nmol/mmol creatinine; P &lt; 0.0001, one‐sided (decrease greater in the BUD group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: significant difference between groups (lower level in BUD group)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Secondary outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PAQLQ(S)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD ‐0.11, 95% CI ‐0.12 to 0.10, one‐sided superiority; <a href="./references#CD010352-fig-0004" title="">Analysis 1.2</a> </p> <p>Non‐inferiority acceptance limits = not provided</p> <p>PP not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square mean) 0.01, 95% CI ‐0.14 to 0.16; <a href="./references#CD010352-fig-0004" title="">Analysis 1.2</a> </p> <p>Non‐inferiority acceptance limit = ‐0.5%</p> <p>PP results were similar</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PACQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD ‐0.08, 95% CI ‐0.27 to 0.11, one‐sided superiority</p> <p>Non‐inferiority acceptance limit not provided</p> <p>PP not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Compliance</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Lung function:</i> FEV<sub>1</sub> (L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.019 L, 95% CI ‐0.059 to 0.022; <a href="./references#CD010352-fig-0005" title="">Analysis 1.3</a> </p> <p>PP: MD (least square means) ‐0.034 L, 95% CI ‐75 to 10</p> <p>Non‐inferiority acceptance limit = ‐100 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.03 L, 95% ‐0.14 to 0.8; <a href="./references#CD010352-fig-0005" title="">Analysis 1.3</a> </p> <p>PP: MD (least square means) ‐0.02 L, 95% CI ‐0.13 to 0.1</p> <p>Non‐inferiority acceptance limit = ‐150 mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Airway inflammation</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b>Not assessed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>BUD: budesonide; CI: confidence interval; CIC: ciclesonide; ITT: intention to treat analysis; MD: mean difference; OD: once daily; PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; PP: per protocol; RR: risk ratio. </p> <p>* Exacerbations were defined as an increasing asthma symptoms requiring change or addition of patient's medication other than increasing rescue medication. </p> <p>** Adverse events that needed treatment, reported in over 2% of patients in CIC or BUD group of safety population (N = 403). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Effect of the intervention: ciclesonide versus budesonide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010352-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects of the intervention: ciclesonide versus fluticasone</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg BID vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg BID vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 160 μg OD vs. FP 88 μg BID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC 80 μg OD vs. FP 88 μg BID</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose ratio</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1:2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0003" title="PedersenS , Garcia‐GarciaML , ManjraA , TheronI , EngelstätterR . A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatric Pulmonology2006;41(10):954‐61. PedersenS , Garcia‐GarciaML , ManjraI , VermeulenH , VenterL , EngelstätterR . Ciclesonide and fluticasone propionate show comparable efficacy in children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , GyurkovitsK , vonDelftKHE , BossH , EngelstätterR . Safety profile of ciclesonide as compared with fluticasone propionate in treatment of children and adolescents with asthma. European Respiratory Journal2004;24(Suppl 48):346s. PedersenS , TheronI , EngelstätterR . Ciclesonide is as effective as fluticasone propionate for treatment of children and adolescents with asthma. Respirology2005;10(Suppl):A25. ">Pedersen 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0001" title="HiremathL , Mohan‐KumarT , SinghV , RamanP , RamspergerU , EngelstätterR . Comparison of once daily ciclesonide 160 µg versus twice daily fluticasone propionate 88 µg in children with moderate to severe asthma. European Respiratory Journal2006;28(Suppl 50):711s. ">Hiremath 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0002" title="PaunovicZ . Comparison of ciclesonide and fluticasone propionate in the treatment of children with persistent asthma. Proceedings of the 29th Congress of the European Academy of Allergy and Clinical Immunology; 2010 June 5‐9; London. ">Paunovic 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010352-bbs2-0004" title="PedersenS , EngelstätterR , WeberHJ , HirschS , BarkaiL , EmerykA , et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics2009;22:214‐20. ">Pedersen 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> asthma symptom score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT and PP:</p> <p>0.00, 95% CI ‐0.29 to 0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>Unclear if ITT or PP *:</p> <p>0.07, 95% CI ‐0.14 to 0.28</p> <p>Non‐inferiority acceptance limit = 0.30 sum score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom score decreased and was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>Unclear if ITT or PP **:</p> <p>0.07, 95% CI ‐0.14 to 0.28</p> <p>Non‐inferiority acceptance limit = 0.30 sum score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> use of rescue medication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT and PP: 0.00, 95% CI ‐1.23 to 2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (Hodges Lehmann point estimate)</p> <p>ITT: CIC: ‐1.13; FP: ‐1.29</p> <p>PP: CIC: ‐1.14; FP: ‐1.29</p> <p>All P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication decreased and was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change from baseline (Hodges Lehmann point estimate)</p> <p>ITT: CIC: ‐1.20; FP: ‐1.29</p> <p>PP: CIC: ‐1.21; FP: ‐1.29</p> <p>All P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms: a</i> sthma symptom‐free days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median difference (Hodges Lehmann point estimate)</p> <p>ITT: ‐1.01, 95% CI ‐4.60 to 2.46</p> <p>PP: ‐1.01, 95% CI ‐4.82 to 2.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Asthma symptoms:</i> % of asthma symptom and rescue medication‐free days combined</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage was high and did not differ significantly between the treatment groups (PP) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>CIC: 91.5%; FP: 94%</p> <p>P = 0.1320 (2‐sided between treatments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PP: mean percentage was high and did not differ between the treatment groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Exacerbations:</i> number of patients with exacerbations</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.26, 95% CI 0.34 to 4.66; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45, 95% CI 0.47 to 4.49; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CIC: 2.3%; FP: 2.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.57, 95% CI 1.35 to 9.47; <a href="./references#CD010352-fig-0006" title="">Analysis 2.1</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> % of patients with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A similar percentage of patients reported adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88, 95% CI 0.72 to 1.07; <a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The incidence of adverse events was similar in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98, 95% CI 0.81 to 1.17; <a href="./references#CD010352-fig-0007" title="">Analysis 2.2</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Adverse events:</i> cortisol 24‐hour urine sample (nmol/mmol)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: difference between 2 groups was not statistically significant</p> <p>ITT and restricted ITT</p> <p>(which included only</p> <p>those urine cortisol</p> <p>measurements with a</p> <p>corresponding urine</p> <p>creatinine value within</p> <p>the normal range)</p> <p>A statistically significant</p> <p>difference in favour of CIC was seen in the restricted ITT analysis</p> <p>(P = 0.006). The findings were similar</p> <p>for patients who were ICS‐naive and patients who had received ICS prior to study entry</p> <p>although the differences were numerically greater in previously ICS‐naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety analysis**: MD</p> <p>0.54 nmol/mmol, 95% CI ‐5.92 to 7.00; <a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety analysis**: MD 1.15 nmol/mmol, 95% CI 0.07 to 2.23; <a href="./references#CD010352-fig-0008" title="">Analysis 2.3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Secondary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PAQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed CIC 160 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = ‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed for CIC80 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = ‐0.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Quality of life:</i> PACQLQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed CIC 160 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT and PP:</p> <p>Non‐inferiority was confirmed for CIC80 compared to FP (P &lt; 0.0001, one‐sided)</p> <p>Non‐inferiority limit = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Compliance</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Change in lung function:</i> </b> </p> <p><b>FEV<sub>1</sub> (L)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) 0.0 L, 95% CI ‐0.042 to 0.042; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) 0.001, 95% ‐0.044 to 0.046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.02 L, 95% CI ‐0.07 to 0.04; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) ‐0.026, 95% CI ‐0.086 to 0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement similar between groups no point estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement similar between groups no point estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITT: MD (least square means) ‐0.05 L, 95% CI ‐0.11 to 0.01; <a href="./references#CD010352-fig-0009" title="">Analysis 2.4</a> </p> <p>PP: MD (least square means) ‐0.056, 95% CI ‐0.12 to ‐0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Airway inflammation</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BID: twice daily; CI: confidence interval; CIC: ciclesonide; FP: fluticasone; ICS: inhaled corticosteroid; ITT: intention to treat analysis; OD: once daily; PACQLQ: Pediatric Asthma Caregiver Quality of Life Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; PP: per protocol analysis. </p> <p>* = In this study analyses were based on PP population and analysis of ITT population was used to confirm results, description of the results are unclear but we assumed it to be based on analysis of PP population. </p> <p>** = safety analysis excluded patients with concurrent nasal, ophthalmological or dermatological corticosteroid treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Effects of the intervention: ciclesonide versus fluticasone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/full#CD010352-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010352-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ciclesonide versus budesonide (dose ratio 1:2)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.75, 6.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life PAQLQ (S) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.09, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FEV<sub>1</sub> least square means (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.10, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ciclesonide versus budesonide (dose ratio 1:2)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010352-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ciclesonide versus fluticasone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dose ratio 1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.58, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dose ratio 1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.35, 9.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: number of patients with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dose ratio 1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.72, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dose ratio 1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: 24‐ hour urine free cortisol adjusted for creatinine (nmol/mmol) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dose ratio 1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐5.92, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dose ratio 1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.07, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Generic FEV<sub>1</sub> least square mean (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dose ratio 1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.04, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dose ratio 1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.11, 0.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ciclesonide versus fluticasone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010352/references#CD010352-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010352&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010352-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010352-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010352-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD010352-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010352"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010352"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010352"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010352\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010352\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010352"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010352&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010352';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010352/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010352/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010352%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725035707"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010352/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725035711"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010352/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e716608121bdf',t:'MTc0MDcyNTAzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 